Clinical application of illness perception intervention in patients with interstitial lung disease based on self-regulation

doi:10.3877/cma.j.issn.1674-6902.2025.05.015

Abstract

Abstract:

Objective

To analyze the clinical application effect of a self-regulation illness perception intervention in patients with interstitial lung disease (ILD).

Methods

A total of 87 ILD patients admitted to our hospital from May 2023 to May 2024 were selected and randomly divided into a control group 43 cases and an intervention group 44 cases. The control group received normal health education, while the observation group adopted self-regulating illness perception intervention on the basis of the control group. Clinical data were compared between the two groups, including forced vital capacity (FVC), forced expiratory volume in the first second (FEV₁), and diffusing capacity of the lungs for carbon monoxide (DLCO), as well as scores from the brief illness perception questionnaire (B-IPQ), acceptance and action questionnaire-Ⅱ (AAQ-Ⅱ), modified british medical research council dyspnea scale, world health organization quality of life brief scale (WHOQOL-BREF), and herth hope index (HHI), assessed before and after the intervention.

Results

After the intervention, the observation group showed FVC (2.74±0.58) L, FEV₁(2.27±0.45)L, and DLCO (17.78±2.11)ml/(mmHg·min), while the control group had FVC (2.70±0.56) L, FEV₁(2.20±0.43) L, and DLCO (17.84±2.56) ml/(mmHg·min). The B-IPQ (43.44±2.93) and AAQ-Ⅱ (23.20±1.95) scores in the observation group were significantly lower than those in the control group B-IPQ(47.31±2.25), AAQ-Ⅱ(25.98±2.43)(P<0.05). Meanwhile, the WHOQOL-BREF physical domain (58.02±4.33), psychological domain (63.01±3.33), and HHI (33.10±2.84) scores in the observation group were significantly higher than those in the control group physical (54.30±3.45), psychological (59.72±3.25), HHI (31.29±3.24)(P<0.05).

Conclusion

Self-regulating perception intervention can improve the illness perception level of patients with ILD and has clinical significance.

Key words: Interstitial lung disease, Illness perception, Self-regulation, Delphi method

Xiaoli Jiang, Jiashuo Xu, Qian Liu, Fangyuan Ren, Zhiling Sun, Juan Zhang, Fangfang Xu, Bi Chen. Clinical application of illness perception intervention in patients with interstitial lung disease based on self-regulation[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2025, 18(05): 747-751.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfbjbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6902.2025.05.015

https://zhfbjbzz.cma-cmc.com.cn/EN/Y2025/V18/I05/747

Figures/Tables 4

References 24

1	王玲，王振发，张佳瑞，等. 预后营养指数对皮肌炎合并间质性肺病的预测价值[J]. 武汉大学学报(医学版): 2025, 46(1): 1-6.
2	Spagnolo P, Distler O, Ryerson CJ, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)[J]. Ann Rheumat Diseases, 2021, 80(2): 143-150.
3	Lu RL, Huang Q, Yu TT, et al. The global burden of heart failure attributable to interstitial lung diseases: insights from the global burden of disease study 2021[J]. BMC Cardiovasc Disord, 2025, 25(1): 262.
4	Mudawi D, Heyes K, Hastings R, et al. An update on interstitial lung disease[J]. Brit J Hospit Med (London, England: 2005), 2021, 82(7): 1-14.
5	王磊，秦瑛. 间质性肺病患者的疾病感知现状及影响因素研究[J]. 中国护理管理，2017, 17(11): 1567-1571.
6	Leventhal H, Phillips LA, Burns E. The common-sense model of self- regulation(CSM): a dynamic framework for understanding illness self-management[J]. J Behav Med, 2016, 39(6): 935946.
7	Mohammadi S, Karim NA, Talib RA, et al. The impact of self-efficacy education based on the health belief model in Iranian patients with type 2 diabetes: a randomised controlled intervention study[J]. Asia Pacific J Clin Nutrit, 2018, 27(3): 546-555.
8	屈京楼，朱亚鑫，曲波. 德尔菲法在医学教育研究中的应用[J]. 中华医学教育杂志，2019, 39(3): 227-230.
9	中华医学会呼吸病学分会，中国医师协会呼吸医师分会. 间质性肺疾病多学科讨论规范中国专家共识[J]. 中华结核和呼吸杂志，2023, 46(12): 1176-1188.
10	Kuiper H, Van Leeuwen CMC, Stolwijk-Swüste JM, et al. Reliability and validity of the brief illness perception questionnaire (B-IPQ) in individuals with a recently acquired spinal cord injury[J]. Clin Rehabilitat, 2022, 36(4): 550-557.
11	Bond FW, Hayes SC, Baer RA, et al. Preliminary psychometric properties of the acceptance and action questionnaire-Ⅱ：a revised measure of psychological inflexibility and experiential avoidance[J]. Behav Ther, 2011, 42(4): 676-688.
12	Siyazbekova Z, Rakhypbekov T, Myssayev A, et al. Using of the World Health Organization quality of life instrument, short form to patient after PCI or CABG surgery[J]. Bratislavske Lekarske Listy, 2022, 123(12): 891-896.
13	Ribeiro S, Cardoso CS, Valério M, et al. Confirmatory evaluation of the modified medical research council questionnaire for assessment of dyspnea in patients with chronic obstructive pulmonary disease in portugal[J]. Acta Med Portug, 2022, 35(2): 89-93.
14	NIkoloudi M, Tsilika E, Parpa E, et al. Herth hope index: A psychometric evaluation study within a sample of greek patients with cancer[J]. Indian J Palliat Care, 2021, 27(3): 367-374.
15	Daniel O, Dest A, Munson A, et al. Interventions to enhance patient and family engagement among adults with multiple chronic conditions: A systematic scoping review[J]. Med Care, 2020, 58(4): 407-416.
16	Parente, R., & Anderson-parente, J. Case study of long-term delphi accuracy[J]. Technolog Forecas Social Change, 2011, 78(9): 1705-1711.
17	杨彩凤. 基于健康商数构建的延续性护理对肺癌患者术后的影响[J]. 中华养生保健，2025, 43(3): 71-73.
18	杨永静，王霞，杨丽. 个体化健康教育应用于慢性病患者自我管理能力的效果研究[J/OL]. 中华肺部疾病杂志(电子版), 2019, 12(6): 794-796.
19	王晨，汤婷，孙晓慧，等. 慢性阻塞性肺疾病患者疾病感知干预方案的构建与应用[J]. 中华护理杂志，2024, 59(11): 1285-1293.
20	李媛，李鑫，胡兴敏，等. 赋能心理护理配合图文教育对小耳畸形耳廓再造术患者围术期疾病感知压力、焦虑及自护能力的影响[J]. 中国健康心理学杂志，2025, 33(4): 592-597.
21	王艺，张凤池，李文艳，等. 多重感知教育对艾滋病患者疾病感知及自我管理能力的影响[J]. 临床护理杂志，2024, 23(6): 14-18.
22	Beyene TJ, Lee CW, Lossie G, et al. Poultry professionals′perception of participation in voluntary disease mapping and monitoring programs in the United States: A cluster analysis[J]. Avian Diseases, 2021, 65(1): 67-76.
23	Wang C, Zhang Z, Wiley JA, et al. Gender differences in pleasure: the mediating roles of cognitive flexibility and emotional expressivity[J]. BMC Psychiat, 2022, 22(1): 320.
24	蔡阿燕，杨洁敏，许爽，等. 表达抑制调节负性情绪的男性优势：来自事件相关电位的证据[J]. 心理学报，2016, 48(5): 482-494.

临床资料	变　量	观察组(n＝44)	对照组(n＝43)	χ²/t值	P值
受教育程度	高中及以上	23(52.27)	25(58.14)	0.303	0.582
	高中以下	21(47.83)	18(41.86)
婚姻状况	已婚	35(79.55)	32(74.42)	0.323	0.570
	未婚/离异/丧偶	9(20.45)	11(25.58)
经济水平	月收入≥5 000元	15(34.09)	17(39.53)	0.277	0.599
	月收入<5 000元	29(65.91)	26(60.47)
吸烟史		27(61.36)	30(69.77)	0.680	0.410
支付方式	自费	7(15.91)	7(16.28)	0.002	0.963
	医保或公费	37(84.09)	36(83.72)
ILD病程	≥5年	25(56.82)	27(62.79)	0.323	0.570
	<5年	19(43.18)	16(37.21)
合并高血压		33(75.00)	37(86.05)	1.688	0.194
合并糖尿病		7(15.91)	5(11.62)	0.335	0.563
合并心脑血管病		8(18.18)	7(16.28)	0.055	0.814
mMRC分级	1~2级	27(61.36)	25(58.14)	0.094	0.759
	3~4级	17(38.64)	18(41.86)
ESR[mm/1 h，(±s)]		36.17±12.23	34.17±9.87	0.840	0.404
LDH[U/L，(±s)]		270.54±55.03	265.63±50.91	0.431	0.667
Scr[μmol/L，(±s)]		78.44±10.92	81.70±14.43	－1.187	0.239
ANA阳性		9(20.93)	15(34.9)	1.886	0.170
KL-6[U/ml，(±s)]		949.42±303.82	845.67±321.62	1.546	0.126

临床资料	变　量	观察组(n＝44)	对照组(n＝43)	χ²/t值	P值
受教育程度	高中及以上	23(52.27)	25(58.14)	0.303	0.582
	高中以下	21(47.83)	18(41.86)
婚姻状况	已婚	35(79.55)	32(74.42)	0.323	0.570
	未婚/离异/丧偶	9(20.45)	11(25.58)
经济水平	月收入≥5 000元	15(34.09)	17(39.53)	0.277	0.599
	月收入<5 000元	29(65.91)	26(60.47)
吸烟史		27(61.36)	30(69.77)	0.680	0.410
支付方式	自费	7(15.91)	7(16.28)	0.002	0.963
	医保或公费	37(84.09)	36(83.72)
ILD病程	≥5年	25(56.82)	27(62.79)	0.323	0.570
	<5年	19(43.18)	16(37.21)
合并高血压		33(75.00)	37(86.05)	1.688	0.194
合并糖尿病		7(15.91)	5(11.62)	0.335	0.563
合并心脑血管病		8(18.18)	7(16.28)	0.055	0.814
mMRC分级	1~2级	27(61.36)	25(58.14)	0.094	0.759
	3~4级	17(38.64)	18(41.86)
ESR[mm/1 h，(±s)]		36.17±12.23	34.17±9.87	0.840	0.404
LDH[U/L，(±s)]		270.54±55.03	265.63±50.91	0.431	0.667
Scr[μmol/L，(±s)]		78.44±10.92	81.70±14.43	－1.187	0.239
ANA阳性		9(20.93)	15(34.9)	1.886	0.170
KL-6[U/ml，(±s)]		949.42±303.82	845.67±321.62	1.546	0.126

肺功能	观察组(n＝44)		P值	对照组(n＝43)		P值
肺功能	治疗前	治疗后	P值	治疗前	治疗后	P值
FVC(L)	2.67±0.68	2.74±0.58	0.071	2.63±0.74	2.70±0.56	0.102
FEV₁(L)	2.16±0.48	2.27±0.45	0.066	2.18±0.54	2.20±0.43	0.064
DLCO ml/(mmHg·min)	16.82±2.66	17.78±2.11	0.168	16.29±2.74	17.84±2.56	0.110

肺功能	观察组(n＝44)		P值	对照组(n＝43)		P值
肺功能	治疗前	治疗后	P值	治疗前	治疗后	P值
FVC(L)	2.67±0.68	2.74±0.58	0.071	2.63±0.74	2.70±0.56	0.102
FEV₁(L)	2.16±0.48	2.27±0.45	0.066	2.18±0.54	2.20±0.43	0.064
DLCO ml/(mmHg·min)	16.82±2.66	17.78±2.11	0.168	16.29±2.74	17.84±2.56	0.110

问卷评分	观察组(n＝44)		P值	对照组(n＝43)		P值
问卷评分	治疗前	治疗后	P值	治疗前	治疗后	P值
B-IPQ[分，(±s)]	52.10±4.83	43.44±2.93	0.023	51.37±4.99	47.31±2.25	0.012
AAQ-Ⅱ[分，(±s)]	26.85±3.02	23.20±1.95	0.019	26.92±2.55	25.98±2.43	0.030
WHOQOL-BREF-生理[分，(±s)]	53.20±3.94	58.02±4.33	0.036	52.39±4.53	54.30±3.45	0.687
WHOQOL-BREF-心理[分，(±s)]	57.93±4.02	63.01±3.33	0.032	58.22±3.42	59.72±3.25	0.741
HHI[分，(±s)]	28.93±3.84	33.10±2.84	0.018	30.28±4.32	31.29±3.24	0.069
mMRC[分，M(Q₁，Q₃)]	2.30 (1.25, 3.00)	2.30 (1.75, 3.00)	0.147	2.30 (1.25, 3.00)	2.20 (1.75, 3.00)	0.041

Please choose a citation manager

Content to export